Leukemia

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

By

Standardized tool improved efficiency and thoroughness of patient assessment and documentation of neurotoxicity caused by high-dose cytarabine.

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

CAR T Cells: Keeping Pace With Adverse Effects of an Emerging Therapy

By

The oncology nurses' role in monitoring and early recognition of the signs and symptoms of CAR T-cell toxicities is significant considering the potential severity of these adverse effects.

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

Protein Suppresses Transformation of Myelodysplastic Syndrome to Acute Myeloid Leukemia

By

Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

Lasting Outcomes for Imatinib in Chronic Myeloid Leukemia

The efficacy of imatinib for CML treatment persisted over time and long-term administration was not associated with unacceptable cumulative effects.

Blinatumomab Increased Overall Survival in B-cell Precursor Acute Lymphoblastic Leukemia

Blinatumomab Increased Overall Survival in B-cell Precursor Acute Lymphoblastic Leukemia

By

Results from the TOWER trial demonstrate that blinatumomab (Blincyto) effectively improved OS in high-risk B-cell precursor ALL.

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

Specialized Cancer Centers May Improve Outcomes in Children with Leukemia

By

The site of cancer care may partially explain survival differences between children and AYAs with ALL.

CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases

CRISPR Illustrates Progression of Normal Blood Cells to Leukemia, Precursor Diseases

By

Genome editing technology illustrates progression of normal blood cells to leukemia.

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

Pediatric Patients, Parents Overreport Adherence to ALL Medication Regimen

By

Pediatric patients and their parents tend to overestimate adherence to anticancer medicine regimen.

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

Lenalidomide Maintenance Appears Efficacious for Relapsed DLBCL

By

Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Idelalisib Increases Progression-Free Survival in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

By

In a study seeking new therapies to improve outcomes for patients with relapsed or refractory CLL, researchers investigated the impact on progression-free survival of adding idelalisib to bendamustine plus rituximab.

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

Allogeneic HCT Effective in Older Patients with AML in Second Complete Remission

By

Researchers determined the curative potential of allogenic hematopoetic stem cell transplantation in patients aged 60 years and older with acute myeloid leukemia in second complete remission.

Two Infants Achieve Leukemia Remission After Gene Therapy

Two Infants Achieve Leukemia Remission After Gene Therapy

By

Two infants with advanced acute lymphoblastic leukemia (ALL) achieved full remission following gene therapy involving modified autologous CAR-T cells.

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase

By

Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.

Researchers Discover Prognostic Genetic Subgroups of a High-Risk Pediatric Leukemia

Researchers Discover Prognostic Genetic Subgroups of a High-Risk Pediatric Leukemia

By

Research from St Jude Children's Research Hospital reveals that acute megakaryoblastic leukemia can be divided into several subgroups with varying prognoses, particularly for children without Down syndrome.

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

Azathioprine Associated With Increased Risk of Myeloid Neoplasms

By

Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

Study Suggest New Treatment Approaches for High-Risk Pediatric Leukemia

By

Three specific genetic alterations may help identify pediatric patients with AMKL at high risk who may benefit from allogeneic stem cell transplants.

Arsenic and APL: Review of Therapy for an Acute Leukemia

Arsenic and APL: Review of Therapy for an Acute Leukemia

By

I was surprised to see an order for arsenic recently. What is this being used for?

What Is The Optimal Sequencing of Novel Agents for CLL?

What Is The Optimal Sequencing of Novel Agents for CLL?

By

Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.

Nilotinib for CML Associated With Improved Quality of Life

Nilotinib for CML Associated With Improved Quality of Life

By

Results of this study reveal the impact on quality of life and consequent adherence to therapy for patients with CML-CP receiving nilotinib as second-line therapy.

Adding Pioglitazone to Imatinib May Improve Response in CML

Adding Pioglitazone to Imatinib May Improve Response in CML

By

Researchers evaluated the molecular response in patients with CML-CP treated with pioglitazone in combination with imatinib, the results of which suggest that adding pioglitazone to a kinase inhibitor may have a synergistic effect.

Ruxolitinib May Improve Symptom Control in Patients With CLL

Ruxolitinib May Improve Symptom Control in Patients With CLL

By

In this study, researchers evaluated whether ruxolitinib, a JAK2 inhibitor that reduces symptoms in patients with myelofibrosis, would improve disease-related symptoms in patients with CLL.

Prenatal Herpes Virus Infection May Increase Childhood Leukemia Risk

Prenatal Herpes Virus Infection May Increase Childhood Leukemia Risk

By

Study results indicate that herpetic cytomegalovirus infection prior to birth subjects the child to increased odds of developing pediatric acute lymphoblastic leukemia.

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

Preventing Tumor Lysis Syndrome in Patients Receiving Venetoclax

By

What precautions should be taken to prevent tumor lysis syndrome (TLS) in patients receiving venetoclax (Venclexta)?

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

Fecal Occult Blood Test, Colonoscopy Useful for Detecting Dasatinib-induced Colitis

By

Researchers examined the frequency of TKI-induced hemorrhagic colitis among patients with CML treated with dasatinib and evaluated the efficacy of screening with a fecal occult blood test followed by colonoscopy in this patient population.

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

Lipid-lowering Drugs May Confer Survival Benefit in Chronic Lymphocytic Leukemia

By

Abnormal lipid metabolism is observed in patients with CLL, prompting an investigation to determine if prevalence of metabolic syndrome is higher in patients with CLL and whether lipid-lowering medications impact survival.

ROR1 Expression May Enhance Disease Progression in CLL

ROR1 Expression May Enhance Disease Progression in CLL

By

Expression of ROR1 could promote leukemia-cell activation and enhance disease progression in patients with chronic lymphocytic leukemia, according to a study.

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

Ibrutinib Effective as Salvage Therapy in Relapsed CLL Following Allogeneic HSCT

By

A report of an evaluation of the benefit of ibrutinib in relapsed CLL following allogeneic HSCT based on an analysis of data from patients with relapsed CLL who received ibrutinib salvage therapy after allogeneic HSCT.

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

5-parameter Prognostic Index Useful for Predicting TTFT, OS in CLL

By

In an observational study of an independent cohort of patients with Binet stage A CLL, researchers sought to validate the ability of the CLL International Prognostic Index to predict time to first treatment (TTFT) and overall survival in patients with early-stage disease.

Study Identifies Factors Associated With Infection-related Complications in ALL

Study Identifies Factors Associated With Infection-related Complications in ALL

By

Data on neutropenia and infection-related complications in patients with ALL are lacking; therefore, this study focused on identifying the characteristics and risk factors of infection-related complications in children with newly diagnosed ALL.

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

Levofloxacin Prophylaxis May Reduce Infection Rate in Relapsed/Refractory AML

By

This study evaluated whether antibacterial prophylaxis effectively reduced the rate of infections overall for patients receiving intensive chemotherapy for relapsed/refractory AML.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs